AI assistant
Sending…
CRISPR Therapeutics AG — Director's Dealing 2016
Oct 18, 2016
30936_dirs_2016-10-18_b62165b6-f32c-4cac-9098-f3150ee9f052.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2016-10-18
Reporting Person: Lundberg Sven Ante (Chief Scientific Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Shares | 450000 | Direct |
| Series B Preferred Shares | 55217 | Direct |
More from CRISPR Therapeutics AG
Regulatory Filings
2026
Jun 5
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 4
Regulatory Filings
2026
May 4
Annual Report
2026
Apr 21
Proxy Solicitation & Information Statement
2026
Apr 21
Director's Dealing
2026
Mar 24
Director's Dealing
2026
Mar 24
Director's Dealing
2026
Mar 24
Director's Dealing
2026
Mar 24
Director's Dealing
2026
Mar 17